PT1947175E - Sequência de nucleótidos e de péptidos gse 24.2 da disquerina, que podem induzir a actividade da telomerase, método para os obter, composições terapêuticas e suas aplicações - Google Patents

Sequência de nucleótidos e de péptidos gse 24.2 da disquerina, que podem induzir a actividade da telomerase, método para os obter, composições terapêuticas e suas aplicações Download PDF

Info

Publication number
PT1947175E
PT1947175E PT06849419T PT06849419T PT1947175E PT 1947175 E PT1947175 E PT 1947175E PT 06849419 T PT06849419 T PT 06849419T PT 06849419 T PT06849419 T PT 06849419T PT 1947175 E PT1947175 E PT 1947175E
Authority
PT
Portugal
Prior art keywords
sequence
cells
pharmaceutical composition
seq
nucleotide sequence
Prior art date
Application number
PT06849419T
Other languages
English (en)
Portuguese (pt)
Inventor
Rosario Perona Abellon
Rosario Machado Pinilla
Leandro Sastre Garzon
Isabel Sanchez Perez
Jose Ramon Murguia Ibanez
Original Assignee
Consejo Superior Investigacion
Univ Madrid Autonoma
Univ Valencia Politecnica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Univ Madrid Autonoma, Univ Valencia Politecnica filed Critical Consejo Superior Investigacion
Publication of PT1947175E publication Critical patent/PT1947175E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
PT06849419T 2005-10-14 2006-10-11 Sequência de nucleótidos e de péptidos gse 24.2 da disquerina, que podem induzir a actividade da telomerase, método para os obter, composições terapêuticas e suas aplicações PT1947175E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200502511A ES2325431B1 (es) 2005-10-14 2005-10-14 Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones.

Publications (1)

Publication Number Publication Date
PT1947175E true PT1947175E (pt) 2010-09-02

Family

ID=38344881

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06849419T PT1947175E (pt) 2005-10-14 2006-10-11 Sequência de nucleótidos e de péptidos gse 24.2 da disquerina, que podem induzir a actividade da telomerase, método para os obter, composições terapêuticas e suas aplicações

Country Status (10)

Country Link
US (2) US9074194B2 (enExample)
EP (1) EP1947175B1 (enExample)
JP (1) JP5560398B2 (enExample)
AT (1) ATE469212T1 (enExample)
CA (1) CA2625981A1 (enExample)
DE (1) DE602006014574D1 (enExample)
DK (1) DK1947175T3 (enExample)
ES (2) ES2325431B1 (enExample)
PT (1) PT1947175E (enExample)
WO (1) WO2007090911A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334736B1 (es) * 2007-11-23 2011-02-02 Consejo Superior De Investigaciones Cientificas (Titular Al 90%) Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular.
WO2014122346A1 (es) * 2013-02-05 2014-08-14 Consejo Superior De Investigaciones Cientificas (Csic) Bionanopartículas biodegradables para liberación del péptido gse24-2, procedimiento de obtención y utilización
WO2015059338A1 (es) 2013-10-25 2015-04-30 Consejo Superior De Investigaciones Científicas (Csic) Péptidos derivados de gse24.2 para tratar enfermedades producidas por estrés oxidativo y daño al adn
WO2020223475A1 (en) * 2019-05-02 2020-11-05 Board Of Regents, The University Of Texas System Methods and compositions involving tert activating therapies
ES2989543A1 (es) * 2023-05-22 2024-11-26 Alodia Farm S L U Peptidos para su uso en la prevencion y/o tratamiento de radiodermitis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
DE19817118C1 (de) * 1998-04-17 1999-10-28 Deutsches Krebsforsch Dyskerin und dafür codierende DNA-Moleküle, diese enthaltende Vektoren, Antikörper gegen Dyskerin und die Verwendung dieser Gegenstände

Also Published As

Publication number Publication date
WO2007090911A1 (es) 2007-08-16
US20150337022A1 (en) 2015-11-26
JP2009511036A (ja) 2009-03-19
EP1947175B1 (en) 2010-05-26
ES2325431A1 (es) 2009-09-03
ATE469212T1 (de) 2010-06-15
CA2625981A1 (en) 2007-08-16
ES2325431B1 (es) 2010-06-28
JP5560398B2 (ja) 2014-07-23
DK1947175T3 (da) 2010-09-27
ES2360238T3 (es) 2011-06-02
DE602006014574D1 (de) 2010-07-08
US20090202503A1 (en) 2009-08-13
US9587002B2 (en) 2017-03-07
EP1947175A1 (en) 2008-07-23
US9074194B2 (en) 2015-07-07

Similar Documents

Publication Publication Date Title
EP0892809B1 (en) Fhit proteins and nucleic acids and methods based thereon
US20230042914A1 (en) Compositions and methods for treatment of homocystinuria
PT724588E (pt) Proteina de ligacao a farmacos
US9587002B2 (en) Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof
JP2006514104A (ja) グリコーゲンシンターゼキナーゼ−３阻害剤
EP0896055B1 (en) Apoptosis inducing protein and gene encoding the same
US20130123340A1 (en) Compositions and methods for the treatment and prevention of cardiac ischemic injury
ES2334736B1 (es) Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular.
KR100399982B1 (ko) Ａｓｋ１과 결합하는 ｃａｄ의 선택적인 저해제로서아폽토시스를 억제하는 신규한 마우스 ｃｉａ 단백질,ｃｉａ 유전자 및 그의 용도
ES2312442T3 (es) Variante alternativa de corte y empalme de glutamina fructosa-6-fosfato amidotransferasa y su producto de expresion.
Perona Abellón et al. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof
SÁNCHEZ PÉREZ TELOMERASE ACTIVITY, METHOD FOR OBTAINING SAME, THERAPEUTIC COMPOSITIONS
WO2003024997A1 (en) Telomerase inhibitory peptides and uses thereof
US20090232787A1 (en) Carcinogen detoxification composition and method
CA2999209A1 (en) Homeoproteins for use in the treatment of neurodegenerative disorders
AU2005253643B2 (en) Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
AU2002325676A1 (en) Telomerase inhibitory peptides and uses thereof
JP2006045228A (ja) 発がん物質を解毒する組成物および方法
JP2003219889A (ja) 新規ｍａｐキナーゼ活性抑制因子
CA2569687A1 (en) Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
CN101240275A (zh) 核苷酸分子septin1sr2及其在制备免疫制剂中的应用
KR20090111728A (ko) Ｊｎｋ1을 유효성분으로 포함하는 ｎｒｌ-매개 안구질환의예방 및 치료용 약학적 조성물